Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The future in treatment of pancreatic cancer

  • 22 Accesses

  • 2 Citations


The mortality rate for pancreatic cancer continues to rise. Despite advances in surgery, radiotherapy, and chemotherapy, the survival rate remains dismal. Future treatment will depend on further epidemiologic, diagnostic, and pathologic studies, as well as controlled clinical trials. Application of new areas of oncologic research to pancreatic cancer is a worthwhile endeavor. Promotion, publication, and dissemination of such research on pancreatic cancer are the goals of the National Pancreatic Cancer Project.


La mortalité du cáncer du pancréas continue à augmenter. Malgré les progrès des diverses méthodes de traitement par chirurgie, irradiation et agents chimiques, le taux de survie est minime. Son amélioration dépend de l'étude approfondie des données de l'épidémiologie, de l'amélioration des méthodes de diagnostic, de la connaissance de la pathologie ainsi que d'essais thérapeutiques bien contrôlés. Les nouvelles méthodes de recherche carcinologique concernent au premier chef le cancer du pancéas; la promotion, la publication, la dissémination de leurs résultats représentent les buts poursuivis aux Etats-Unis par le Projet National de Recherche sur le Cancer du pancréas.


La mortalidad del cancer pancreático continúa en aumento. A pesar de los avances en cirugía, radioterapia y quimioterapia la tasa de sobrevida se mantiene lúgubre. El tratamiento future dependerá del desarrollo de nuevos estudios sobre los aspectos epidemiológicos, diagnósticos y patológicos, así como de la ejecución de ensayos clińicos controlados. La aplicación de las nuevas áreas de investigación oncológica al cancer pancreático es un esfuerzo que merece ser estimulado. La promoción, publicación y diseminación de este tipo de investigación sobre el cáncer pancreático son los objetivos del Proyecto Nacional de Cáncer Pancreático emprendido por el Instituto Nacional de Cáncer de los Estados Unidos.

This is a preview of subscription content, log in to check access.


  1. 1.

    Whipple, A.O., Parsons, W.B., Mullins, C.R.: Treatment of carcinoma of the ampulla of Vater. Ann. Surg.102:763, 1935

  2. 2.

    Maingot, R.: Pancreatic tumors and periampullary carcinomas. In Abdominal Operations, R. Maingot, editor. New York, Appleton-Century-Crofts, 1980, pp. 920–949

  3. 3.

    van Heerden, J.A., ReMine, W.H., Weiland, L.H., McIlrath, D.C., Ilstrup, D.M.: Total pancreatectomy for ductal adenocarcinoma of the pancreas. Mayo Clinic experience. Am. J. Surg.142:308, 1981

  4. 4.

    Fortner, J.G., Kim, D.K., Cubilla, A., Turnbull, A., Pahnke, L.D., Shils, M.E.: Regional pancreatectomy: En bloc pancreatic portal vein and lymph node resection. Ann. Surg.186:42, 1977

  5. 5.

    Howard, J.M.: Pancreatico-duodenectomy: Fortyone consecutive Whipple resections without an operative mortality. Ann. Surg.168:629, 1968

  6. 6.

    Aoki, K., Ogawa, H.: I. Cancer of the pancreas, international mortality trends. World Health Stat.31:2, 1978

  7. 7.

    Silverberg, E.: Cancer statistics, 1984. CA34:7, 1984

  8. 8.

    Smith, F.P., Hoth, D.F., Levin, B., Karlin, D.A., Macdonald, J.S., Woolley, P.V., III, Schein, P.S.: 5-fluorouracil, Adriamycin, and mitomycin C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer46:2014, 1980

  9. 9.

    Metzger, U.F., Kisner, D.L., Ghosh, B.C.: Combined modality treatment of pancreatic cancer: Implications for the surgeon. J. Surg. Oncol.24:107, 1983

  10. 10.

    Kern, H.F., Adler, G., von Bulow, M., Klöppel, G.: Fine structural differentiation of cell types in normal human pancreatic duct system and in different grades of pancreatic adenocarcinoma. Dig. Dis. Sci.28:937, 1983

  11. 11.

    Satake, K., Shim, K., Umeyama, K.: Electron microscopic examination of human pancreatic adenocarcinoma. Dig. Dis. Sci.28:947, 1983

  12. 12.

    Bell, R.H., Jr., Hye, R.J., Strayer, D.S.: Do pancreatic islets have a role in the development of exocrine pancreatic cancer? Dig. Dis. Sci.28:926, 1983

  13. 13.

    Bulow, M.V., Klöppel, G., Kern, H., Scharfe, T., Baisch, G.: Establishment and characterization of long-term tissue cultures of human exocrine pancreas carcinoma. Dig. Dis. Sci.28:929, 1983

  14. 14.

    Chang, B.K., Black, O., Jr., Gutman, R.: Combined effects of α-difluoromethylornithine (DFMO) and doxorubicin (DOX) against pancreatic cancer cell lines in culture. Dig. Dis. Sci.28:930, 1983

  15. 15.

    Marx, M., Townsend, C.M., Jr., Barranco, S.C., Glass, E.J., Thompson, J.C.: Treatment of pancreatic cancer by α-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis. Dig. Dis. Sci.28:941, 1983

  16. 16.

    Townsend, C.M., Jr., Marx, M., Glass, E.J., Thompson, J.C.: Medroxyprogesterone stimulates growth of pancreatic carcinoma. Dig. Dis. Sci.28:950, 1983

  17. 17.

    Greenway, B.A., Iqbal, M.J., Johnson, P.J., Williams, R.: Exocrine carcinoma of the pancreas; the role of the sex-steroids in its growth and treatment. Dig. Dis. Sci.28:935, 1983

  18. 18.

    Clemente, F., Ruellan, C., Scemama, J.L., Estival, A., Fogh, J., Ribet, A.: VIP, somatostatin and dopamine receptors in the human pancreatic cancer cell line Capan-1. Dig. Dis. Sci.28:931, 1983

  19. 19.

    Campanale, R.P., II, Frey, C.F., Twomey, P.L., Guernsey, J.M.: Reliability and sensitivity of frozen section pancreatic biopsy. Dig. Dis. Sci.28:929, 1983

  20. 20.

    Campanale, R.P., II, Farias, L.R., Twomey, P.L., Frey, C.F., Guernsey, J.M., Keehn, R., Higgins, G.: Sensitivity of wedge vs. needle biopsy in the intraoperative diagnosis of pancreatic cancer. Dig. Dis. Sci.28:929, 1983

  21. 21.

    Dritschilo, A., Piro, A.J.: Therapeutic implications of heat as related to radiation therapy. Semin. Oncol.8:83, 1981

  22. 22.

    Clement, J.J., Gorman, M.S., Wodinsky, I., Catane, R., Johnson, R.K.: Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res.40:4165, 1980

  23. 23.

    Dougherty, T.J., Thoma, R.E., Boyle, D.G., Weishaupt, K.R.: Interstitial photoradiation therapy for primary solid tumors in pet cats and dogs. Cancer Res.41:401, 1981

  24. 24.

    Selby, P., Buick, R.N., Tannock, I.: A critical appraisal of the “human tumor stem-cell assay”. N. Engl. J. Med.308:129, 1983

  25. 25.

    Diamond, B., Scharff, M.D.: Monoclonal antibodies. J.A.M.A.248:3165, 1982

Download references

Author information

Correspondence to Isidore Cohn Jr. M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dietzen, C.D., Cohn, I. The future in treatment of pancreatic cancer. World J. Surg. 8, 952–955 (1984). https://doi.org/10.1007/BF01656037

Download citation


  • Public Health
  • Clinical Trial
  • Mortality Rate
  • Survival Rate
  • Pancreatic Cancer